Inhibitors
1 paper1 finding
- 1 lab in 1 country
- Funders: National Institute of Neurological Disorders and Stroke and others
- Cells1
Outcomes
1Cellular senescence
downin human cells1
1 study
Cellular senescence
downin human cells1
Inhibitors decrease cellular senescence in human cells.
“Targeting selected factors with specific inhibitors, we ameliorated some aspects of the paracrine spreading of senescence in a brain cell-type-dependent manner.”
Cellsin human brain cell types
Characterizing the SASP-Dependent Paracrine Spreading of Senescence Between Human Brain Cell Types
Aging cell1 Aug 2026
Funding
34 grants since 2023National Institute of Diabetes and Digestive and Kidney DiseasesUS$11.6mNational Institute on AgingUS$11.8mNational Heart, Lung, and Blood InstituteUS$4m
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using SGLT2 Inhibitors
National Heart, Lung, and Blood InstituteUniversity of Illinois at ChicagoUS$755.9k2025–2030
National Institute of Diabetes and Digestive and Kidney DiseasesAdventhealth OrlandoUS$2.5m2025–2028
National Institute of Diabetes and Digestive and Kidney DiseasesEmory UniversityUS$676.6k2021–2027
Continuous ketone monitoring with the use of SGLT2 inhibitors in T1D
National Institute of Diabetes and Digestive and Kidney DiseasesMcGill UniversityUS$123.3k2025–2029
Role of Integrase Strand Transfer Inhibitors on Hypertension in People with HIV
National Heart, Lung, and Blood InstituteUniversity of Alabama at BirminghamUS$223.4k2025–2027
Pharmacokinetics (PK) and Pharmacodynamics (PD) Characterization of mTOR Inhibitors in Older Adults
National Institute on AgingUT Southwestern Medical CenterUS$607.5k2024–2027
Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis
National Heart, Lung, and Blood InstituteFibronoxUS$1.1m2024–2027
Sodium Glucose Cotransporter-2 Inhibitors for the Amelioration of Acute Cardio-Renal Syndrome
National Institute of Diabetes and Digestive and Kidney DiseasesYale UniversityUS$193.8k2025–2030
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of Texas Hlth Science CenterUS$674.2k1998–2027
Elucidating Drug Interactomes for Cardiac Protection by SGLT2 Inhibitors
National Heart, Lung, and Blood InstituteStanford UniversityUS$131.1k2025–2027